La Chandra Pharmalab Profile
Key Indicators
- Authorised Capital ₹ 7.19 M
as on 20-12-2024
- Paid Up Capital ₹ 6.18 M
as on 20-12-2024
- Company Age 11 Year, 22 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 27.36 Cr
as on 20-12-2024
- Satisfied Charges ₹ 12.50 Cr
as on 20-12-2024
- Revenue 61.48%
(FY 2022)
- Profit 54.13%
(FY 2022)
- Ebitda -69.34%
(FY 2022)
- Net Worth 105.86%
(FY 2022)
- Total Assets 31.23%
(FY 2022)
About La Chandra Pharmalab
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 7.19 M and a paid-up capital of Rs 6.18 M.
The company currently has active open charges totaling ₹27.36 Cr. The company has closed loans amounting to ₹12.50 Cr, as per Ministry of Corporate Affairs (MCA) records.
Chandrabhan Gadhvi, Priyvrat Gadhvi, and Vratika Gadhvi serve as directors at the Company.
- CIN/LLPIN
U24230GJ2013PTC078033
- Company No.
078033
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Dec 2013
- Date of AGM
18 Jul 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at La Chandra Pharmalab?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Priyvrat Gadhvi  | Director | 26-Dec-2013 | Current |
| Chandrabhan Gadhvi | Director | 27-Mar-2018 | Current |
| Vratika Gadhvi | Director | 26-Feb-2015 | Current |
Financial Performance of La Chandra Pharmalab.
La Chandra Pharmalab Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 61.48% increase. The company also saw a substantial improvement in profitability, with a 54.13% increase in profit. The company's net worth Soared by an impressive increase of 105.86%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of La Chandra Pharmalab?
In 2023, La Chandra Pharmalab had a promoter holding of 73.56% and a public holding of 26.44%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Sidbi Creation Date: 09 Nov 2023 | ₹2.51 Cr | Open |
Hdfc Bank Limited Creation Date: 18 Nov 2022 | ₹18.42 Cr | Open |
Sidbi Creation Date: 13 Oct 2022 | ₹1.49 Cr | Open |
How Many Employees Work at La Chandra Pharmalab?
La Chandra Pharmalab has a workforce of 59 employees as of Jun 25, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of La Chandra Pharmalab, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped La Chandra Pharmalab's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
